Reviewer’s report

Title: The Src inhibitor dasatinib stimulates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

Version: 2 Date: 17 February 2010

Reviewer: Olivia Fromigue

Reviewer’s report:

What is the right answer between :"Indeed, the stimulatory effects of dasatinib are clearly and significantly detected ... on RANKL expression level at days 3 and 7" and "Difference between DAG and Dasatinib+DAG conditions on RANKL expression at day 7 (new Fig.9) is not significant" ?

I recognize that a complete analysis of glucocorticoid supplementation on src activity may be addressed separately but as the Authors performed supplemental experiments using western blot analysis, what is the effect of dexamethasone on src phosphorylation status?

Dasatinib is not sufficient to induce osteoblastic differentiation when it is used alone. However, even if it can transiently favor dexamethasone-induced differentiation, the global effect on matrix calcification is significant at day 14 but no after that time (DAG vs DAG+dasatinib = NS at day 21; figure 8A).

The title and the conclusions must be modified because of overstating the results.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests